Division of Hematology and Oncology

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Neoplasms 86%
3. Breast Neoplasms 77%
4. Survival 66%
5. Cell Transplantation 61%
6. Therapeutics 60%
7. Acute Myeloid Leukemia 54%
8. Transplants 54%
9. Drug Therapy 52%
10. Neoplasm Metastasis 46%
11. Diphosphonates 45%
12. Bone and Bones 45%
13. Allogeneic Cells 45%
14. Bone Marrow 44%
15. Zoledronic Acid 41%
16. Carboplatin 40%
17. Paclitaxel 39%
18. Graft vs Host Disease 37%
19. Leukemia 36%
20. Hematopoietic Stem Cell Transplantation 33%
21. Lung Neoplasms 32%
22. Multiple Myeloma 29%
23. Stem Cell Transplantation 27%
24. Recurrence 26%
25. Docetaxel 26%
26. Progression-Free Survival 24%
27. Radiotherapy 24%
28. Small Cell Lung Carcinoma 24%
29. Pharmacokinetics 23%
30. T-Lymphocytes 23%
31. Terpenes 22%
32. Tissue Donors 22%
33. Transplantation 21%
34. Cyclophosphamide 21%
35. Pamidronate 21%
36. Prostatic Neoplasms 21%
37. Aminoglutethimide 20%
38. Mutation 20%
39. ErbB Receptors 20%
40. Immunotherapy 19%
41. Cisplatin 19%
42. Stem Cells 19%
43. Pancreatic Neoplasms 19%
44. Busulfan 19%
45. Biomarkers 19%
46. Bone Marrow Transplantation 18%
47. Hematologic Neoplasms 18%
48. Bone Diseases 17%
49. Safety 17%
50. Confidence Intervals 17%
51. Carcinoma 17%
52. Aromatase Inhibitors 17%
53. gemcitabine 17%
54. Denosumab 16%
55. Serum 16%
56. Platinum 16%
57. Protein-Tyrosine Kinases 15%
58. Hematopoietic Stem Cells 15%
59. Lymphoma 15%
60. Cell Line 15%
61. Myelodysplastic Syndromes 14%
62. Placebos 14%
63. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14%
64. Unrelated Donors 14%
65. Proteins 14%
66. Lovastatin 14%
67. Mortality 14%
68. Genes 14%
69. Clinical Trials 13%
70. Bone Neoplasms 13%
71. Melanoma 13%
72. Lung 13%
73. Growth 13%
74. Blood Platelets 12%
75. Etoposide 12%
76. geranylgeranyl pyrophosphate 12%
77. Pemetrexed 12%
78. Incidence 12%
79. Phosphotransferases 12%
80. Pharmaceutical Preparations 12%
81. Radiation 12%
82. farnesyl pyrophosphate 12%
83. Erlotinib Hydrochloride 12%
84. Prenylation 11%
85. Tamoxifen 11%
86. Quality of Life 11%
87. Cytarabine 11%
88. Renal Cell Carcinoma 11%
89. Peripheral Blood Stem Cells 11%
90. Population 11%
91. Adenocarcinoma 10%
92. Osteoclasts 10%
93. Apoptosis 10%
94. Protein Prenylation 10%
95. Blood Cells 10%
96. Methotrexate 10%
97. Rituximab 10%
98. Bone Resorption 10%